1-palmitoyl-2-oleoyl-3-acetylglycerol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 1-palmitoyl-2-oleoyl-3-acetylglycerol
• 英文别名: 1-Palmitoyl-2-oleoyl-3-acetyl-glycerol；(1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (Z)-octadec-9-enoate
• 化学式: C₃₉H₇₂O₆
• 分子量: 636.997
• InChiKey: BFGDEKPANYJEBP-HNENSFHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.8
• 重原子数：
  45
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甘油棕榈酸酯 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-palmitoyl-2-oleoyl-3-acetylglycerol
  参考文献：
  名称：

  Monoacetyldiglycerides as new Ca2+ mobilizing agents in rat pancreatic acinar cells

  摘要：

  Several monoacetyldiglycerides were synthesized from glycerol in search fbr new Ca2+ mobilizing agent in vitro. All monoacetyldiglycerides except linolenoyl and phenlycyclopropylcarbonyl derivatives showed activity toward Ca2+ release in pancreatic acinar cells. Linoleoyl and docosahexaenoyl derivatives were chosen for further test and exhibited unique activity. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00690-8

文献信息

• COMPOSITION CONTAINING MONOACETYLDIACYLGLYCEROL COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING ASTHMA
  申请人：Enzychem Lifesciences Corporation

  公开号：EP3037091A1

  公开（公告）日：2016-06-29

  The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

  本发明涉及一种含有单乙酰二乙酰甘油化合物作为有效成分的预防或治疗哮喘的药物组合物，以及一种预防或治疗哮喘的功能性保健食品组合物。本发明的单乙酰二乙酰甘油化合物可抑制 EL-4 细胞（小鼠 T 细胞淋巴瘤细胞）中 IL-4 的表达，降低哮喘诱导动物模型中气道的超敏性，并抑制炎症细胞向支气管的浸润。此外，本发明的化合物还能抑制血清和支气管肺泡灌洗液中 IgE 的生成，在抑制肺部 Th2 细胞因子（IL-4、IL-5 和 IL-13）的表达方面效果极佳，从而克服了目前使用的哮喘治疗剂的副作用，且无毒性，治疗效果显著，因此可用作预防、治疗和缓解哮喘的组合物。
• COMPOSITION CONTAINING MONOACETYLDIACYLGLYCEROL COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES
  申请人：Enzychem Lifesciences Corporation

  公开号：EP3037093A1

  公开（公告）日：2016-06-29

  The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

  本发明涉及一种含有单乙酰二乙酰甘油化合物作为活性成分的药物组合物，用于预防或治疗慢性阻塞性肺病，以及一种用于治疗或预防慢性阻塞性肺病的功能性保健食品组合物。本发明的单乙酰二乙酰甘油化合物可抑制 EL-4 细胞中 IL-4 的表达，并可抑制动物模型中炎症细胞向支气管的浸润。此外，本发明的化合物在抑制 CXCL-1、TNF-α 或 MIP-2 的表达方面具有很好的效果，从而克服了目前使用的慢性阻塞性肺病治疗剂的副作用，无毒性，治疗效果显著，因此可作为预防、治疗和缓解慢性阻塞性肺病的组合物。
• Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
  申请人：ENZYCHEM LIFESCIENCES CORPORATION

  公开号：US10098864B2

  公开（公告）日：2018-10-16

  The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

  本发明涉及一种含有单乙酰二乙酰甘油化合物作为有效成分的预防或治疗哮喘的药物组合物，以及一种预防或治疗哮喘的功能性保健食品组合物。本发明的单乙酰二乙酰甘油化合物可抑制 EL-4 细胞（小鼠 T 细胞淋巴瘤细胞）中 IL-4 的表达，降低哮喘诱导动物模型中气道的超敏性，并抑制炎症细胞向支气管的浸润。此外，本发明的化合物还能抑制血清和支气管肺泡灌洗液中 IgE 的生成，在抑制肺部 Th2 细胞因子（IL-4、IL-5 和 IL-13）的表达方面效果极佳，从而克服了目前使用的哮喘治疗剂的副作用，且无毒性，治疗效果显著，因此可用作预防、治疗和缓解哮喘的组合物。
• Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease
  申请人：ENZYCHEM LIFESCIENCES CORPORATION

  公开号：US10765655B2

  公开（公告）日：2020-09-08

  The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

  本发明涉及一种含有单乙酰二乙酰甘油化合物作为活性成分的药物组合物，用于预防或治疗慢性阻塞性肺病，以及一种用于治疗或预防慢性阻塞性肺病的功能性保健食品组合物。本发明的单乙酰二乙酰甘油化合物可抑制 EL-4 细胞中 IL-4 的表达，并可抑制动物模型中炎症细胞向支气管的浸润。此外，本发明的化合物在抑制 CXCL-1、TNF-α 或 MIP-2 的表达方面具有很好的效果，从而克服了目前使用的慢性阻塞性肺病治疗剂的副作用，无毒性，治疗效果显著，因此可作为预防、治疗和缓解慢性阻塞性肺病的组合物。
• Methods for Inducing Stem Cell Migration and Specialization with EC-18
  申请人：Hong John J.

  公开号：US20100010087A1

  公开（公告）日：2010-01-14

  The present invention relates to promoting stem cell migration and specialization by administering one or more MADG compounds. The present invention further pertains to repairing or promoting the healing of injured tissue or a wound of an individual by administering a MADG compound (e.g., EC-18) to the individual, or subjecting the injured tissue/wound to a MADG compound. Another aspect of the invention relates to treating disease or conditions that benefit from stem cell therapy by administering MADG with or without exogenous stem cells.